Amgen Details Phase 3 Dazodalibep Results in Sjogren Disease

Recovered 36-hour item: Amgen disclosed detailed randomized Phase 3 OASIZ-301 results November 11 after earlier topline news. Both dazodalibep dose schedules improved systemic disease activity at week 48 versus placebo in Sjögren disease.





